RFM
BNGO icon

Royal Fund Management’s Bionano Genomics BNGO Stock Holding History

Royal Fund Management’s Portfolio BNGO Stock Details BNGO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-17
Closed -$13K – 216
2022
Q2 		$13K Hold
17
– – ﹤0.01% 198
2022
Q1 		$25K Hold
17
– – ﹤0.01% 203
2021
Q4 		$29K Buy
+17
New +$45.5K ﹤0.01% 191

Other funds holding BNGO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Mitsubishi UFJ Asset Management
Mitsubishi UFJ Asset Management Tokyo, Japan $149B AUM 24.71% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Royal Fund Management's BNGO Position: Q3 2022 in Review

Royal Fund Management sold out of Bionano Genomics (BNGO) in Q3 2022, closing a stake of 17 shares — an estimated $13K sold.

Royal Fund Management first reported a position in BNGO in Q4 2021 and held it in 3 quarters. The position peaked at $29K in Q4 2021. 140 funds tracked by Wall St. Rank hold BNGO as of Q3 2022.

  • Royal Fund Management reported no remaining Bionano Genomics position as of Q3 2022 after selling out during the quarter.
  • Royal Fund Management sold 17 Bionano Genomics shares in Q3 2022, an estimated $13K.
  • Royal Fund Management first reported a position in Bionano Genomics in Q4 2021 and held it in 3 quarters.
  • Royal Fund Management's Bionano Genomics position peaked at $29K in Q4 2021.
  • 140 funds tracked by Wall St. Rank held Bionano Genomics as of Q3 2022.

Based on Royal Fund Management's 13F filing for Q3 2022, filed 14 Nov 2022.